PMID- 23422504
OWN - NLM
STAT- MEDLINE
DCOM- 20130628
LR  - 20190221
IS  - 1095-6859 (Electronic)
IS  - 0090-8258 (Linking)
VI  - 129
IP  - 3
DP  - 2013 Jun
TI  - Prognostic role of cyclooxygenase-2 in epithelial ovarian cancer: a meta-analysis 
      of observational studies.
PG  - 613-9
LID - S0090-8258(13)00082-6 [pii]
LID - 10.1016/j.ygyno.2013.02.011 [doi]
AB  - OBJECTIVE: The aim of this study was to evaluate the prognostic significance of 
      cyclooxygenase-2 (COX-2) on survival in patients with ovarian cancer by using a 
      meta-analysis of observational studies. METHODS: We searched Pubmed and Embase to 
      retrieve observational studies evaluating the association between COX-2 status 
      and survival in patients with ovarian cancer. Hazards ratios (HRs) or odds ratios 
      (ORs) with 95% confidence intervals (CIs) were pooled across studies using a 
      random-effects model. RESULTS: A total of 17 studies were included in this 
      meta-analysis to estimate the association between COX-2 and overall survival 
      (OS), disease-free survival (DFS), response to chemotherapy (RC), and other 
      clinical parameters. In a random-effects meta-analysis of 15 studies, higher 
      COX-2 expression significantly predicted poor OS (death HR, 1.34; 95% CI, 
      1.05-1.71; I(2)=56.5%). A more prominent association was found between COX-2 
      expression and poor OS when studies with adjustment for age, stage, and histology 
      were included (death HR, 1.65; 95% CI, 1.25-2.17; I(2)=0%). However, higher COX-2 
      expression was not significantly associated with poor DFS (recurrence HR, 1.36; 
      95% CI, 0.79-2.33; I(2)=53.6%) and RC (OR, 1.89; 95% CI, 0.85-4.21; I(2)=17.6%). 
      There was a marginally significant association between COX-2 positivity and 
      several clinical parameters such as age, stage, and histology. The pooled ORs of 
      higher COX-2 expression were 1.75 (95% CI, 1.01-3.04) for advanced stages, 1.34 
      (95% CI, 0.97-1.85) for old age, and 1.42 (95% CI, 0.98-2.05) for serous cancer 
      in histologic type, respectively. CONCLUSIONS: The present meta-analysis suggests 
      that higher COX-2 expression may be an independent risk factor for poor OS in 
      patients with ovarian cancer.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Lee, Jung-Yun
AU  - Lee JY
AD  - Department of Obstetrics and Gynecology, Seoul National University College of 
      Medicine, Seoul, Republic of Korea.
FAU - Myung, Seung-Kwon
AU  - Myung SK
FAU - Song, Yong-Sang
AU  - Song YS
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130217
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
SB  - IM
MH  - Carcinoma, Ovarian Epithelial
MH  - Cyclooxygenase 2/*biosynthesis/metabolism
MH  - Female
MH  - Humans
MH  - Neoplasms, Glandular and Epithelial/*enzymology
MH  - Observation
MH  - Ovarian Neoplasms/*enzymology
MH  - Prognosis
EDAT- 2013/02/21 06:00
MHDA- 2013/07/03 06:00
CRDT- 2013/02/21 06:00
PHST- 2012/12/12 00:00 [received]
PHST- 2013/02/08 00:00 [revised]
PHST- 2013/02/10 00:00 [accepted]
PHST- 2013/02/21 06:00 [entrez]
PHST- 2013/02/21 06:00 [pubmed]
PHST- 2013/07/03 06:00 [medline]
AID - S0090-8258(13)00082-6 [pii]
AID - 10.1016/j.ygyno.2013.02.011 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2013 Jun;129(3):613-9. doi: 10.1016/j.ygyno.2013.02.011. Epub 2013 
      Feb 17.